Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
INFI's Cash to Debt is ranked higher than
96% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. INFI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
INFI' s 10-Year Cash to Debt Range
Min: 0.28   Max: 13254
Current: No Debt

0.28
13254
Equity to Asset 0.45
INFI's Equity to Asset is ranked lower than
74% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. INFI: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
INFI' s 10-Year Equity to Asset Range
Min: -0.03   Max: 0.94
Current: 0.45

-0.03
0.94
F-Score: 5
Z-Score: 0.43
M-Score: 2.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -34.98
INFI's Operating margin (%) is ranked higher than
57% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -73.33 vs. INFI: -34.98 )
Ranked among companies with meaningful Operating margin (%) only.
INFI' s 10-Year Operating margin (%) Range
Min: -6986.21   Max: 22.94
Current: -34.98

-6986.21
22.94
Net-margin (%) -40.42
INFI's Net-margin (%) is ranked higher than
55% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. INFI: -40.42 )
Ranked among companies with meaningful Net-margin (%) only.
INFI' s 10-Year Net-margin (%) Range
Min: -6967.24   Max: 28.35
Current: -40.42

-6967.24
28.35
ROE (%) -38.56
INFI's ROE (%) is ranked lower than
59% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. INFI: -38.56 )
Ranked among companies with meaningful ROE (%) only.
INFI' s 10-Year ROE (%) Range
Min: -123.36   Max: 27.59
Current: -38.56

-123.36
27.59
ROA (%) -24.46
INFI's ROA (%) is ranked lower than
51% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: -23.47 vs. INFI: -24.46 )
Ranked among companies with meaningful ROA (%) only.
INFI' s 10-Year ROA (%) Range
Min: -51.92   Max: 16.29
Current: -24.46

-51.92
16.29
ROC (Joel Greenblatt) (%) -572.05
INFI's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. INFI: -572.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INFI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3156.78   Max: 338.58
Current: -572.05

-3156.78
338.58
Revenue Growth (3Y)(%) -0.90
INFI's Revenue Growth (3Y)(%) is ranked lower than
51% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. INFI: -0.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INFI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 155.9
Current: -0.9

0
155.9
EBITDA Growth (3Y)(%) -55.50
INFI's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 426 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. INFI: -55.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
INFI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -64.6   Max: 261.4
Current: -55.5

-64.6
261.4
EPS Growth (3Y)(%) -37.90
INFI's EPS Growth (3Y)(%) is ranked lower than
86% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. INFI: -37.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
INFI' s 10-Year EPS Growth (3Y)(%) Range
Min: -64   Max: 115.9
Current: -37.9

-64
115.9
» INFI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

INFI Guru Trades in Q2 2014

Chuck Royce 123,400 sh (New)
Steven Cohen 3,410,978 sh (unchged)
John Burbank Sold Out
Jim Simons 198,600 sh (-60.16%)
Steven Cohen 3,411,659 sh (-4.05%)
» More
Q3 2014

INFI Guru Trades in Q3 2014

Paul Tudor Jones 16,163 sh (New)
Chuck Royce 135,400 sh (+9.72%)
Steven Cohen 500,000 sh (unchged)
Steven Cohen 1,700,000 sh (-50.16%)
Jim Simons 42,800 sh (-78.45%)
» More
Q4 2014

INFI Guru Trades in Q4 2014

Steven Cohen 52,476 sh (New)
Jim Simons 201,600 sh (+371.03%)
Steven Cohen Sold Out
Chuck Royce Sold Out
Paul Tudor Jones 12,679 sh (-21.56%)
» More
Q1 2015

INFI Guru Trades in Q1 2015

Lee Ainslie 17,200 sh (New)
Jim Simons 668,000 sh (+231.35%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INFI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 54.95
INFI's Forward P/E is ranked lower than
86% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 21.19 vs. INFI: 54.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 4.90
INFI's P/B is ranked lower than
54% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. INFI: 4.90 )
Ranked among companies with meaningful P/B only.
INFI' s 10-Year P/B Range
Min: 0.68   Max: 51.23
Current: 4.9

0.68
51.23
P/S 3.60
INFI's P/S is ranked higher than
81% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. INFI: 3.60 )
Ranked among companies with meaningful P/S only.
INFI' s 10-Year P/S Range
Min: 1.32   Max: 60.95
Current: 3.6

1.32
60.95
PFCF 11.10
INFI's PFCF is ranked higher than
87% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. INFI: 11.10 )
Ranked among companies with meaningful PFCF only.
INFI' s 10-Year PFCF Range
Min: 2.17   Max: 48.64
Current: 11.1

2.17
48.64
POCF 10.98
INFI's POCF is ranked higher than
87% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 31.64 vs. INFI: 10.98 )
Ranked among companies with meaningful POCF only.
INFI' s 10-Year POCF Range
Min: 2.09   Max: 30
Current: 10.98

2.09
30
Current Ratio 5.40
INFI's Current Ratio is ranked higher than
57% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. INFI: 5.40 )
Ranked among companies with meaningful Current Ratio only.
INFI' s 10-Year Current Ratio Range
Min: 0.64   Max: 17.81
Current: 5.4

0.64
17.81
Quick Ratio 5.40
INFI's Quick Ratio is ranked higher than
58% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. INFI: 5.40 )
Ranked among companies with meaningful Quick Ratio only.
INFI' s 10-Year Quick Ratio Range
Min: 0.41   Max: 17.81
Current: 5.4

0.41
17.81
Days Sales Outstanding 1.39
INFI's Days Sales Outstanding is ranked higher than
97% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 63.44 vs. INFI: 1.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
INFI' s 10-Year Days Sales Outstanding Range
Min: 0.18   Max: 831.54
Current: 1.39

0.18
831.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.30
INFI's Price/Net Cash is ranked higher than
84% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. INFI: 7.30 )
Ranked among companies with meaningful Price/Net Cash only.
INFI' s 10-Year Price/Net Cash Range
Min: 0.87   Max: 38.43
Current: 7.3

0.87
38.43
Price/Net Current Asset Value 7.30
INFI's Price/Net Current Asset Value is ranked higher than
84% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 15.30 vs. INFI: 7.30 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INFI' s 10-Year Price/Net Current Asset Value Range
Min: 0.81   Max: 398.67
Current: 7.3

0.81
398.67
Price/Tangible Book 5.20
INFI's Price/Tangible Book is ranked higher than
77% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. INFI: 5.20 )
Ranked among companies with meaningful Price/Tangible Book only.
INFI' s 10-Year Price/Tangible Book Range
Min: 0.74   Max: 46
Current: 5.2

0.74
46
Price/Median PS Value 0.90
INFI's Price/Median PS Value is ranked higher than
79% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. INFI: 0.90 )
Ranked among companies with meaningful Price/Median PS Value only.
INFI' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 13.73
Current: 0.9

0.34
13.73
Earnings Yield (Greenblatt) -15.10
INFI's Earnings Yield (Greenblatt) is ranked lower than
70% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. INFI: -15.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
INFI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14.6   Max: 4271.1
Current: -15.1

-14.6
4271.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:I3F.Germany,
Infinity Pharmaceuticals Inc was incorporated in California on March 22, 1995 under the name IRORI and, in 1998; the Company changed its name to Discovery Partners International, Inc. On September 12, 2006, Discovery Partners completed a merger with Infinity Pharmaceuticals, Inc., to which a wholly-owned subsidiary of Discovery Partners merged with and into the Company. The Company is a biopharmaceutical company engaged in discovering, developing and delivering medicines to people with difficult-to-treat diseases. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. The IPI-145, its primary product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K. The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in white blood cells, where they have distinct and mostly non-overlapping roles in immune cell development and function. For Hematologic Malignancies, the Company has launched DUETTS, an investigation of IPI-145 in blood cancers. As part of the DUETTS program, it is conducting DYNAMO, a Phase 2, open-label, single arm study evaluating the safety and efficacy of IPI-145 dosed at 25mg BID in approximately 120 patients with indolent non-Hodgkin lymphoma, or iNHL, including follicular lymphoma, marginal zone lymphoma and small lymphocytic lymphoma, whose disease is refractory to radio immunotherapy or both rituximab and chemotherapy. The FDA has granted orphan drug designation to IPI-145 for the potential treatment of follicular lymphoma. It is conducting DUO, a randomized, monotherapy Phase 3 study of IPI-145 in approximately 300 patients with relapsed/refractory chronic lymphocytic leukemia. For Inflammation and Autoimmune Diseases, the Company has completed a Phase 1, randomized, double-blind, placebo-controlled trial of IPI-145 in healthy adult subjects designed to support the development of IPI-145 in inflammatory and autoimmune diseases. The Company is also developing its second PI3K product candidate, a potent, oral inhibitor of PI3K-delta and gamma referred to as IPI-443. The nonclinical studies of IPI-443 required for Phase 1 development have been completed, and the data from the two Phase 2 studies of IPI-145 in inflammatory and autoimmune diseases will guide the next steps for the development of IPI-443. The Company has discovered IPI-940, a novel, orally available inhibitor of fatty acid amide hydrolase. It is believed that inhibition of FAAH may enable the body to bolster its own analgesic and anti-inflammatory response and may have applicability in a broad range of painful or inflammatory conditions. The Company has five issued or allowed U.S. patents covering IPI-145 and/or other molecules related to PI3K program, which expires on various dates between 2029 and 2031. In addition, it has approximately 170 patents and patent applications pending related to PI3K progr
» More Articles for INFI

Headlines

Articles On GuruFocus.com

More From Other Websites
3:44 am Infinity Pharmaceutical reports Phase 1 data showing clinical activity of Duvelisib;... Jun 01 2015
Infinity Reports Phase 1 Data Showing Clinical Activity of Duvelisib in Treatment-Naïve Patients... May 31 2015
Infinity Reports Phase 1 Data Showing Clinical Activity of Duvelisib in Treatment-Naïve Patients... May 31 2015
Infinity to Participate in Three Investor Conferences in June May 27 2015
Infinity to Participate in Three Investor Conferences in June May 27 2015
Infinity Reports Preclinical Data for Duvelisib Demonstrating Synergy with Standard-of-Care... May 26 2015
Infinity Reports Preclinical Data for Duvelisib Demonstrating Synergy with Standard-of-Care... May 26 2015
Infinity Announces New Data for Duvelisib to Be Presented at the 2015 American Society of Clinical... May 13 2015
Infinity Announces New Data for Duvelisib to Be Presented at the 2015 American Society of Clinical... May 13 2015
On the move: New hires and appointments in the local life sciences industry May 11 2015
Infinity Pharmaceuticals Hits Its Limit May 08 2015
Street Talk: Bullish Amazon call May 07 2015
Coverage initiated on Infinity Pharmaceutical by Deutsche Bank May 07 2015
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... May 07 2015
Infinity Reports First Quarter 2015 Financial Results and Recent Corporate Developments May 06 2015
Infinity Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today May 06 2015
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 06 2015
Infinity reports 1Q loss May 06 2015
Infinity reports 1Q loss May 06 2015
INFINITY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK